Immunic Inc (IMUX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $102.61M
Last updated: Nov 17, 2026 at 11:05 AM ET
Immunic Inc (IMUX) Stock Forecast
Analysts expect Immunic (IMUX) to earn -$3.56 per share in the fiscal year ending Dec 31, 2026. Of 13 analysts, 13 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 6 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 13 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 13
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$3.56
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$2.37
- EPS consensus
- Next report
- Feb 24, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$3.56 | -$5.72 to -$3.09 | 12 |
| Dec 31, 2027 | -$2.37 | -$4.77 to -$0.70 | 11 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.82 | -$1.23 to -$0.60 | 13 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 12 upward and 5 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 6 | 3 |
| Fiscal year ending Dec 31, 2027 | 6 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$4.40.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.56 | -$3.56 | -$3.57 | -$3.57 | -$4.40 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.37 | -$2.36 | -$2.43 | -$2.43 | -$3.63 | N/A |
Frequently Asked Questions About IMUX
What is the IMUX stock forecast?
Consensus analyst estimates put Immunic's EPS at -$3.56 for the fiscal year ending Dec 31, 2026. The consensus rating from 13 analysts is Buy.
How do analysts rate IMUX stock?
Of 13 analysts covering Immunic, 0 rate it Strong Buy, 13 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from IMUX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.56, with estimates from -$5.72 to -$3.09 from 12 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.37, with estimates from -$4.77 to -$0.70 from 11 analysts.
How many analysts cover IMUX?
13 analysts rate Immunic stock, and 12 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
IMUX pages: Overview, Earnings, Forecast, Financials, Competitors